Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis

Thrombosis Research

Volumn 123, Issue 1, 2008, Pages 146-158

  Bird, J Eileen ^a   Giancarli, Mary R ^a   Allegretto, Nick ^a   Barbera, Frank ^a   Wong, Pancras ^a   Schumacher, William A ^a   Ogletree, Martin L ^a   Seiffert, Dietmar ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Argatroban; Aspirin; Clopidogrel; Hirudin; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CLOPIDOGREL; FERRIC CHLORIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRUDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; THROMBIN INHIBITOR; TIROFIBAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS SHUNT; ARTICLE; BLEEDING TIME; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DRUG EFFECT; GUINEA PIG; HEMOSTASIS; KIDNEY HEMORRHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

ANIMALS; ANTICOAGULANTS; ARTERIOVENOUS SHUNT, SURGICAL; ASPIRIN; BLEEDING TIME; FERRIC COMPOUNDS; GUINEA PIGS; HEMOSTASIS; MALE; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TYROSINE;

EID: 54049089615     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.03.010     Document Type: Article

References (33)

1. Andrade-Gordon P., Derian C.K., Maryanoff B.E., Zhang H.C., Addo M.F., Cheung W.M., et al. Administration of a potent antagonist of protease- activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 298 (2001) 34-42
2. Ogawa T., Sugidachi A., Naganuma K., and Asai F. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs. Thromb Res 97 (2000) 307-315
3. Roux S., Carteaux J.P., Hess P., Falivene L., and Clozel J.P. Experimental carotid thrombosis in the guinea pig. Thromb Haemost 71 (1994) 252-256
4. Aoki T., Cox D., Senzaki K., Seki J., Tanaka A., Takasugi H., et al. Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model. Thromb Res 89 (1998) 129-136
5. 1 and argatroban. J Pharmacol Exp Ther 277 (1996) 502-510
6. Moriguchi A., Maeda M., Mihara K., Aoki T., Matsuoka N., and Mutoh S. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban. J Cereb Blood Flow Metab 25 (2005) 75-86
7. Sato K., Kawasaki T., Hisamichi N., Taniuchi Y., Hirayama F., Koshio H., et al. Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs. Eur J Pharmacol 350 (1998) 87-91
8. Carteaux J.P., Gast A., Tschopp T.B., and Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 91 (1995) 1568-1574
9. Dascombe W.H., Hong C., Garrett K.O., White J.G., Lyle V.A., Miller J.L., et al. Artificial microvascular graft thrombosis: the consequences of platelet membrane glycoprotein Ib inhibition and thrombin inhibition. Blood 82 (1993) 126-134
10. 2, ADP and thrombin in thrombogenesis in the guinea pig. Eur J Pharmacol 231 (1993) 421-425
11. Kato Y., Kita Y., Hirasawa-Taniyama Y., Nishio M., Mihara K., Ito K., et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 473 (2003) 163-169
12. 2 synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding. Eur J Pharmacol 417 (2001) 217-222
13. Moritani Y., Sato K., Shigenaga T., Hisamichi N., Ichihara M., Akamatsu S., et al. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist. Eur J Pharmacol 439 (2002) 43-52
14. Cook J., Holahan M., Lyle E.A., Ramjit D.R., Sitko G.R., Stranieri M.T., et al. Nonpeptide glycoprotein IIb/IIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther 278 (1996) 62-73
15. Himber J., Refino C.J., Burcklen L., Roux S., and Kirchhofer D. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb Haemost 85 (2001) 475-481
16. Gurevitz O., Eldar M., Skutelsky E., Tamarin I., Shenkman B., Eskaraev R., et al. S-nitrosoderivative of a recombinant fragment of von willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model. Thromb Haemost 84 (2000) 912-917
17. Himber J., Kirchhofer D., Riederer M., Tschopp T.B., Steiner B., and Roux S.P. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 78 (1997) 1142-1149
18. Schumacher W.A., Bostwick J.S., Ogletree M.L., Stewart A., Steinbacher T.E., Hua J., et al. Biomarker optimization to track the antithrombotic and haemostatic effects of clopidogrel in rats. J Pharmacol Exper Ther 322 (2007) 369-377
19. 2 production in healthy subjects. Thromb Res 17 (1980) 317-327
20. Lanas A.I., Arroyo M.T., Esteva R., Cornudella R., Hirshcowitz B.I., and Sainz R. Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut 39 (1996) 654-660
21. Tran H., and Anand S.S. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 292 (2004) 1867-1874
22. The CUAPRETI Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation. N Engl J Med 345 (2001) 494-502
23. CAPRIE Steering Committee. A randomized, blind, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 348 (1996) 1329-1339
24. Boneu B., and Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 76 (1996) 939-943
25. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338 (1998) 1488-1497
26. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96 (1997) 1445-1453
27. Markwardt F. Development of hirudin as an antithrombotic agent. Semin thromb hemost 15 (1989) 269-282
28. Salzet M. Leech thrombin inhibitors. Curr Pharm Des 8 (2002) 493-503
29. Greinacher A., Eichler P., Lubenow N., Kwasny H., and Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta -analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96 (2000) 846-851
30. Harrington R.A., Bekcer R.C., Ezekiwitz M., Meade T.W., O'Connor C.M., Vorchheimer D.A., et al. Antithrombotic therapy for coronary artery disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 513-548
31. Elg M., Gustafsson D., and Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 94 (1999) 187-197
32. Lewis B.E., Wallis D.E., Berkowitz S.D., Matthai W.H., Fareed J., Walenga J.M., et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103 (2001) 1838-1843
33. Schumacher W.A., Heran C.L., and Steinbacher T.E. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. J Cardiovasc Pharmacol 28 (1996) 19-25